CurifyLabs announced that it has raised $14 million in Series A funding to expand its personalized medicine platform. The round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors, including Lifeline Ventures. The round also included participation from U.S. customers and employees. CurifyLabs said the funding will be used to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation.
CurifyLabs is a health technology company focused on transforming how personalized medicines are made. Its Compounding System Solution combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate personalized medication preparation.
The company said its platform enables tailored doses and dosage forms to be produced with greater precision and speed than manual pharmacy processes. Advanced quality control processes are also built into the system.
Pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses each day. As demand grows, CurifyLabs plans to invest in its supply chain so pharmacy partners have access to the materials and support they need.
The funding will also support ongoing development of the CurifyLabs platform. This includes PharmaPrinter Aurum, the company’s latest product, which compounds up to nine times faster than manual processes.
CurifyLabs’ technology is ISO 13485 certified. The platform is also designed in compliance with FDA 503A and 503B standards for non-sterile compounding.
Founded in 2021, CurifyLabs serves compounding pharmacies by helping them deliver precise, patient-specific therapies efficiently and reliably. The company is headquartered in Helsinki, Finland, and Jacksonville, Florida.
Sandwater invests in deep-tech and impact-driven companies across energy, resource efficiency, robotics, AI, and health. HealthCap is a European life sciences venture firm, while Tesi is a state-owned Finnish investment company focused on venture capital, private equity, and growth companies.
KEY QUOTES:
“Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way. CurifyLabs has built something rare — technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond.”
Morten E. Iversen, Partner at Sandwater
“We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution. The CurifyLabs team has done exactly that.”
Daniel Karsberg, Partner at HealthCap
“CurifyLabs is the kind of company we want to support — innovative, globally ambitious, and built on deep scientific expertise. Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage.”
Joni Karsikas, Investment Director at Tesi
“This investment reflects the conviction our partners have in what we’re building. We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
Charlotta Topelius, CEO and Founder of CurifyLabs
